Economists say Australia shouldn’t try to transition to net zero by aping the mammoth US Inflation Reduction Act 
Impact of Iran-Israel conflict on Stocks, Gold and Bitcoin 
Will global oil supply be at risk if Iran and Israel pull the Middle East into war? 
Taxes aren’t just about money – they shape how we think about each other 
Industry shutdowns are messy and painful: 4 lessons Australia’s coal sector can learn from car-makers about bowing out 
United Airlines Adjusts Aircraft Delivery Plans Amid Boeing Delays 
Naver Pay, Billboard Ink MOU for Fintech-Entertainment Services; Billboard Korea to Launch in June 
How cuts to marginal income tax could boost the UK’s stagnant economic growth 
Huawei Unveils Pura 70 Series to Rival Apple's Dominance in China's Smartphone Arena 
Why Africa can be the beating heart of South Korea’s technology industry 
The Original Mouthful: McDonald's Australia Revives Legendary Big Mac Chant with a Tech Twist 
Samsung Implements Emergency 6-Day Work Week to Combat Slowing Growth 
PUMA and BMW MMS Launch Vibrant Crews Go Summer Collection 
Why is toddler milk so popular? Follow the money 
PUMA and Mercedes-AMG PETRONAS F1 Team Launch Crews Go Summer Collection 
‘Grand Theft Auto’ Game Publisher Take-Two Interactive to Layoff Employees, Discontinue Projects 
Celltrion and Mirae Asset were said to have agreed on buying the largest stake in the UK-headquartered antibody-drug conjugates developer, Iksuda Therapeutics. Based on the report, the deal between the companies is worth $47 million.
The stake acquisition deal
As per The Korea Economic Daily, with its huge investment, Celltrion Inc. is expecting to expand its cancer drug line. The biopharmaceutical company headquartered in Incheon, South Korea, wants to develop more treatments in addition to its Truxima, a blood cancer drug, and Herzuma for breast cancer.
It was said that Iksuda has four ADC-based drugs that are already in pre-clinical development, including B-cell lymphomas. Celltrion can make use of these once the deal is fully completed.
ADC is an advanced technology that was created to specifically target a cancer cell. In any case, Celltrion and Mirae Asset have paid half of the investment price to the British biotech firm, and the rest of the payment will be delivered once agreed development milestones are reached.
"This stake investment will create synergy with our antibody treatments and add next-generation anticancer drugs to our pipeline," a Celltrion official said.
The benefits from the investments for Iksuda
Celltrion and Mirae Asset’s investment in Iksuda Therapeutics will make them the largest stakeholder in the UK-based company. The funding coming from the Korean firms will go to the development and advancement of Iksuda’s lead ADC assets and other technologies.
It was mentioned that Iksuda’s lead pre-clinical drug is called IKS03, and it is said to be a “best-in-class” CD19-targeted ADC candidate for B-cell cancers. Celltrion and Mirae’s multi-million investment will be used for IKSO3 to progress from its first human phase 1 clinical trial.
“This is a transformational investment milestone for Iksuda, enabling us to focus on the progression of our industry-leading ADC programs and bring them to the clinic, whilst supporting our commercial growth,” Iksuda Therapeutics CEO, Dr.Dave Simpson, said in a press release. “The funding not only reflects the potential of our technologies but also the unmatched expertise of the Iksuda team. We are grateful for the support of this group of investors and delighted to welcome them to the team.
